ANNA LEENA SIREN

Summary

Affiliation: Max Planck Institute for Experimental Medicine
Country: Germany

Publications

  1. ncbi Differential glial and vascular expression of endothelins and their receptors in rat brain after neurotrauma
    A L Siren
    Department of Psychiatry, Georg August University, and Max Planck Institute for Experimental Medicine, Goettingen, Germany
    Neurochem Res 25:957-69. 2000
  2. ncbi Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain
    A L Siren
    Max Planck Institute for Experimental Medicine, Hermann Rein Strasse 3, 37075 Gottingen, Germany
    Acta Neuropathol 101:271-6. 2001
  3. ncbi Proinflammatory cytokine expression contributes to brain injury provoked by chronic monocyte activation
    A L Siren
    Department of Neurology, The Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Mol Med 7:219-29. 2001
  4. ncbi Erythropoietin--a novel concept for neuroprotection
    A L Siren
    Max Planck Institute for Experimental Medicine, Goettingen, Germany
    Eur Arch Psychiatry Clin Neurosci 251:179-84. 2001
  5. ncbi Endothelin B receptor deficiency augments neuronal damage upon exposure to hypoxia-ischemia in vivo
    ANNA LEENA SIREN
    Department of Neurology, Georg August University, and Max Planck Institute for Experimental Medicine, Hermann Rein Strasse 3, D 37075 Gottingen, Germany
    Brain Res 945:144-9. 2002
  6. ncbi A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain
    Hannelore Ehrenreich
    Max Planck Institute of Experimental Medicine, Georg August University, 37075 Goettingen, Germany
    Proc Natl Acad Sci U S A 102:862-7. 2005
  7. ncbi Erythropoietin therapy for acute stroke is both safe and beneficial
    Hannelore Ehrenreich
    Max Planck Institute for Experimental Medicine, Departments of Neurology and Psychiatry, Georg August University, Goettingen, Germany
    Mol Med 8:495-505. 2002
  8. ncbi Hippocampal cannabinoid-1 receptor upregulation upon endothelin-B receptor deficiency: a neuroprotective substitution effect?
    Christian Unzicker
    Division of Clinical Neuroscience, Max Planck Institute for Experimental Medicine, Gottingen, Germany
    Neurochem Res 30:1305-9. 2005
  9. ncbi Erythropoietin: novel approaches to neuroprotection in human brain disease
    Hannelore Ehrenreich
    Clinical Neuroscience Laboratory, Max Planck Institute for Experimental Medicine, Gottingen, Germany
    Metab Brain Dis 19:195-206. 2004
  10. ncbi A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia
    Hannelore Ehrenreich
    Max Planck Institute for Experimental Medicine, Hermann Rein Str 3, 37075 Gottingen, Germany
    Transfus Apher Sci 31:39-44. 2004

Collaborators

Detail Information

Publications14

  1. ncbi Differential glial and vascular expression of endothelins and their receptors in rat brain after neurotrauma
    A L Siren
    Department of Psychiatry, Georg August University, and Max Planck Institute for Experimental Medicine, Goettingen, Germany
    Neurochem Res 25:957-69. 2000
    ..These changes seem to be posttranscriptional and cell type specific. They favor vasoconstriction increasing the risk of late vasospasm and ischemia...
  2. ncbi Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain
    A L Siren
    Max Planck Institute for Experimental Medicine, Hermann Rein Strasse 3, 37075 Gottingen, Germany
    Acta Neuropathol 101:271-6. 2001
    ....
  3. ncbi Proinflammatory cytokine expression contributes to brain injury provoked by chronic monocyte activation
    A L Siren
    Department of Neurology, The Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Mol Med 7:219-29. 2001
    ..The effect of chronic monocyte activation on the development of cerebral infarcts was thus studied in rats after provocation of a modified local Swartzman reaction, in brain vasculature...
  4. ncbi Erythropoietin--a novel concept for neuroprotection
    A L Siren
    Max Planck Institute for Experimental Medicine, Goettingen, Germany
    Eur Arch Psychiatry Clin Neurosci 251:179-84. 2001
    ....
  5. ncbi Endothelin B receptor deficiency augments neuronal damage upon exposure to hypoxia-ischemia in vivo
    ANNA LEENA SIREN
    Department of Neurology, Georg August University, and Max Planck Institute for Experimental Medicine, Hermann Rein Strasse 3, D 37075 Gottingen, Germany
    Brain Res 945:144-9. 2002
    ..n=5, P=0.0560). To conclude, absence of functional ETB receptors is associated with an increased susceptibility to HI in-vivo, which is not intrinsic to neurons. Antagonism of ETB receptors seems not to be desirable in ischemic stroke...
  6. ncbi A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain
    Hannelore Ehrenreich
    Max Planck Institute of Experimental Medicine, Georg August University, 37075 Goettingen, Germany
    Proc Natl Acad Sci U S A 102:862-7. 2005
    ..This effect is not only inhibited by EPO but also by neurotrophins. We suggest that the proapoptotic function of TPO helps to select for neurons that have acquired target-derived neurotrophic support...
  7. ncbi Erythropoietin therapy for acute stroke is both safe and beneficial
    Hannelore Ehrenreich
    Max Planck Institute for Experimental Medicine, Departments of Neurology and Psychiatry, Georg August University, Goettingen, Germany
    Mol Med 8:495-505. 2002
    ..EPO protects neurons from hypoxic/ ischemic injury. The objective of this trial is to study the safety and efficacy of recombinant human EPO (rhEPO) for treatment of ischemic stroke in man...
  8. ncbi Hippocampal cannabinoid-1 receptor upregulation upon endothelin-B receptor deficiency: a neuroprotective substitution effect?
    Christian Unzicker
    Division of Clinical Neuroscience, Max Planck Institute for Experimental Medicine, Gottingen, Germany
    Neurochem Res 30:1305-9. 2005
    ..We suggest that CB1-receptor upregulation in the ETB-mutant hippocampus reflects an attempt to compensate for the lack of ETB-receptors...
  9. ncbi Erythropoietin: novel approaches to neuroprotection in human brain disease
    Hannelore Ehrenreich
    Clinical Neuroscience Laboratory, Max Planck Institute for Experimental Medicine, Gottingen, Germany
    Metab Brain Dis 19:195-206. 2004
    ....
  10. ncbi A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia
    Hannelore Ehrenreich
    Max Planck Institute for Experimental Medicine, Hermann Rein Str 3, 37075 Gottingen, Germany
    Transfus Apher Sci 31:39-44. 2004
    ..At the moment a multicenter study is being carried out in Germany...
  11. ncbi Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis
    Hannelore Ehrenreich
    Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Georg August University, Gottingen, Germany
    Brain 130:2577-88. 2007
    ..There were no adverse events, no safety concerns and a surprisingly low need of blood-lettings. This first pilot study demonstrates the necessity and feasibility of controlled trials using high-dose rhEPO in chronic progressive MS...
  12. ncbi Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root ganglia
    Wolfgang Knabe
    Department of Anatomy Embryology, Georg August University Gottingen, Kreuzbergring 36, 37075 Gottingen, Germany
    Anat Embryol (Berl) 210:209-19. 2005
    ....
  13. ncbi Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation
    Christiane Albert-Weissenberger
    Department of Neurology, University Clinic of Würzburg, Wurzburg, Germany
    J Cereb Blood Flow Metab 32:1747-56. 2012
    ..Inhibition of B1R may become a novel strategy to counteract trauma-induced neurodegeneration...
  14. ncbi Characterization of binding kinetics of [3H]Tyr-D-Arg2-Phe-Sar4 at opioid receptors
    Stefan Vonhof
    Department of Cardiology and Pneumology, Georg August University, Robert Koch Str 40, 37075 Gottingen, Germany
    Eur J Pharmacol 473:127-34. 2003
    ..Thus, [3H]TAPS, depending on the presence of divalent cations, serves as ligand at two MOP receptor binding sites in the calf thalamus, which may represent distinct affinity states of the same receptor or receptor subtypes thereof...